Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older

Oren Auster, Uriah Finkel, Noa Dagan, Noam Barda, Alon Laufer, Ran D Balicer, Shay Ben-Shachar

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction
On July 29, 2021, concerns of waning immunity after Pfizer-BioNTech BNT162B2 mRNA vaccination led the Israeli Ministry of Health to start a campaign to administer booster (third) doses to individuals who received their second dose at least 5 months prior.1,2 The booster was initially approved for individuals 60 years or older. This survey study assessed the occurrence of adverse effects (AEs) in adults 60 years or older who received a booster dose.
Original languageEnglish
Pages (from-to)e227657
JournalJAMA network open
Volume5
Issue number4
DOIs
StatePublished - 1 Apr 2022

ASJC Scopus subject areas

  • Medicine (all)

Fingerprint

Dive into the research topics of 'Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older'. Together they form a unique fingerprint.

Cite this